R&D in Early Detection
Although the past two decades have seen remarkable advances in
the development of oncological therapeutics and personalized
cancer treatments, early detection/diagnosis remains the most effective
way of saving lives. Reniguard is developing mutation
assays for the early detection and risk assessment of certain
cancers. Reniguard is also developing
assays for the early diagnosis of drug-resistance during
treatment of chronic hepatitis B.
Cancer is a genetic disease caused by mutations or a
combination of mutations with epigenetic modifications.
These cancer-derived genetic materials, when detected from
body fluids (blood, urine, etc), can provide useful
information for cancer risk
assessment, early diagnosis, post-surgery monitoring and prognosis
purposes. However, this requires the detection methods to be ultra-sensitive
and preferably quantitative. Body
normal non-mutated DNAs which suppress the detection of
mutated DNAs. As the amount of mutated DNAs is very
little compared with the amount of normal DNAs at the early
stage, detecting mutated DNAs is like finding "a needle in a haystack" .
Scientists at Reniguard have developed mutation detection
technologies that have detection sensitivities as high as 0.1 -
0.001%. This level of sensitivity makes early detection
possible. We also have strong expertise in other aspects
of assay development that are crucial to early detection.
Publications & Presentations
Development of Hepatocellular Carcinoma in
Patients with Chronic Hepatitis B Long After Achieving HBsAg
Seroconversion: A Need for an Improved Hepatitis B Virus DNA
Assay. Clin Microbial 2:127, 2013
Ultrasensitive Quantification of HBV
Mutants and Potential Clinical Applications (Invited
presentation), 14th International Symposium on Viral Hepatitis
and liver Disease (ISVHLD), June 2012
Ultrasensitive Quantification of Complex
DNA Mutations (Presentation), BIOMARKER WORLD CONGRESS 2012
Quantitative dynamics of hepatitis B basal
core promoter and precore mutants before and after HBeAg
seroconversion. Journal of Hepatology. 56:795-802, 2012.
Quantification of complex precore
mutations of hepatitis B virus by SimpleProbe real time PCR
and dual melting analysis. Journal of Clinical Virology.
Ultrasensitive quantification of hepatitis
B virus A1762T/G1764A mutant by a SimpleProbe PCR using a
wild-type-selective PCR blocker and a primer-blocker-probe
partial-overlap approach. Journal of Clinical
Microbiology. 49(7):2440-2448, 2011
HBV Drug Resistance Development, Testing
and Prevention. Current Hepatitis Reports.
Rapid and sensitive
detection of hepatitis B virus 1762T/1764A double mutation
from hepatocellular carcinomas using LNA-mediated PCR clamping
and hybridization probes. J Virol Methods. 158:24-29, 2009.